ArticleGland surgery2025
Radiotherapy as a surgical alternative in ductal carcinoma in situ (DCIS): long-term survival benefits and predictors of invasive progression risk.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, the incidence of ductal carcinoma in situ (DCIS) is gradually increasing. Considering its overall favorable prognosis, some studies have explored exempting patients from surgery for potentially low-risk patients. This retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database investigates whether omitting surgery and administering only local radiotherapy (RT) affects the prognosis of patients. Methods: A total of 2,363 patients with DCIS who did not receive surgery were identified from the SEER database. Propensity score matching (PSM) and Kaplan-Meier method were applied to analyze the impact of RT alone. Cox regression analyses and competitive risk models were used to examine factors related to the progression of DCIS to invasive cancer. Results: After PSM, there were 194 patients in each of the RT and non-RT groups. Overall survival (OS) at 10 years (93.17% RT Conclusions: Based on the study of the SEER database, we found that RT alone can effectively improve patient outcomes, with a relatively low 10-year iBCP rate. Factors such as histological type, tumor size, histological grade, and hormone receptor status can influence the survival benefits and risk of RT alone for invasive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.